Evidence map›Paper›PMID 38938409›Full record

ArticleBiology methods & protocols2024

PROMER technology: A new real-time PCR tool enabling multiplex detection of point mutation with high specificity and sensitivity.

Hwanhee Nam, Esder Lee, Hichang Yang, Kyeyoon Lee, Taeho Kwak, Dain Kim, Hyemin Kim, Mihwa Yang, Younjoo Yang, Seungwan Son and 2 more

Abstract read
In one paragraph

Article in Biology methods & protocols, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hwanhee NamInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, United States.
Esder LeeNuriBio Co., Ltd, Anyang-si, Gyeonggi-Do, 14058, Republic of Korea.
Hichang YangNuriBio Co., Ltd, Anyang-si, Gyeonggi-Do, 14058, Republic of Korea.
Kyeyoon LeeNuriBio Co., Ltd, Anyang-si, Gyeonggi-Do, 14058, Republic of Korea.
Taeho KwakNuriBio Co., Ltd, Anyang-si, Gyeonggi-Do, 14058, Republic of Korea.
Dain KimNuriBio Co., Ltd, Anyang-si, Gyeonggi-Do, 14058, Republic of Korea.
Hyemin KimNuriBio Co., Ltd, Anyang-si, Gyeonggi-Do, 14058, Republic of Korea.
Mihwa YangNuriBio Co., Ltd, Anyang-si, Gyeonggi-Do, 14058, Republic of Korea.
Younjoo YangNuriBio Co., Ltd, Anyang-si, Gyeonggi-Do, 14058, Republic of Korea.
Seungwan SonNuriBio Co., Ltd, Anyang-si, Gyeonggi-Do, 14058, Republic of Korea.
Young-Hyean NamNuriBio Co., Ltd, Anyang-si, Gyeonggi-Do, 14058, Republic of Korea.
Il MinnInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, United States.ORCID https://orcid.org/0000-0002-7822-662X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Real-time polymerase chain reaction (real-time PCR) is a powerful tool for the precise quantification of nucleic acids in various applications. In cancer management, the monitoring of circulating tumor DNA (ctDNA) from liquid biopsies can provide valuable information for precision care, including treatment selection and monitoring, prognosis, and early detection. However, the rare and heterogeneous nature of ctDNA has made its precise detection and quantification challenging, particularly for ctDNA containing hotspot mutations. We have developed a new real-time PCR tool, PROMER technology, which enables the precise and sensitive detection of ctDNA containing cancer-driven single-point mutations. The PROMER functions as both a PRObe and priMER, providing enhanced detection specificity. We validated PROMER technology using synthetic templates with known KRAS point mutations and demonstrated its sensitivity and linearity of quantification. Using genomic DNA from human cancer cells with mutant and wild-type KRAS, we confirmed that PROMER PCR can detect mutant DNA. Furthermore, we demonstrated the ability of PROMER technology to efficiently detect mutation-carrying ctDNA from the plasma of mice with human cancers. Our results suggest that PROMER technology represents a promising new tool for the precise detection and quantification of DNA containing point mutations in the presence of a large excess of wild-type counterpart.

Indexed as

cell-free DNAcirculating tumor DNAKRAS mutationsliquid biopsyreal-time PCR

Identifiers

PMID38938409
PMCPMC11208725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.